Alterations in lipid kinetics in men with HIV-dyslipidemia.
about
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.HIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR/GR co-regulation.Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysisImpaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.HIV protease inhibitors and obesityCombination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular diseaseHypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemiaThe pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines.Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy.Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.Viral mechanisms of adipose dysfunction: lessons from HIV-1 VprA Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.Maternal post-absorptive leucine kinetics during late pregnancy in US women with HIV taking antiretroviral therapy: a cross-sectional pilot study.The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism.Body composition and metabolic changes in HIV-infected patientsCellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic AnalysisDecrease in hepatic very-low-density lipoprotein-triglyceride secretion after weight loss is inversely associated with changes in circulating leptin.HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk.Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.Metabolic syndrome risks of cardiovascular disease: differences between HIV-positive and HIV-negative?Treatment of dyslipidemia in HIV-infected patients.Treatment of dyslipidemia in HIV.HIV1-viral protein R (Vpr) mutations: associated phenotypes and relevance for clinical pathologies.Adipose Tissue in HIV Infection.Reproducibility of stable isotope-labeled tracer measures of VLDL-triglyceride and VLDL-apolipoprotein B-100 kinetics.HIV infection does not prevent the metabolic benefits of diet-induced weight loss in women with obesity.Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.Biochemical Manifestation of HIV Lipodystrophy Syndrome.Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia.Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia.Effects of transgenic expression of HIV-1 Vpr on lipid and energy metabolism in mice
P2860
Q25255216-D3C86F41-227C-49F5-B3BF-CBA8EDCA50DCQ33562238-D6934064-E57E-428D-B848-88CAD7725F80Q34312147-BFC569B5-ED33-4CDC-A539-0B39D2B95AA8Q34512603-9B0C22E5-7DC7-444E-998D-A104417BF5F9Q34564973-C6529E9B-BD5D-4D5D-82F5-5380FAA85221Q34792983-5BB752E9-4139-42A0-8E08-E644F7F523A2Q35101789-518F5400-0DC8-4D37-AB32-1BA907072338Q35104006-0DD9D366-CED9-463F-89E6-F1B442D8A850Q35176441-19DA0442-5E18-4FE2-988B-0B34E9E3C2CCQ35384143-8B50EF62-12DA-4C5E-91CA-BD097D400E74Q35607320-651D0217-3497-4F9B-A425-4D20CE6A4ECBQ35739799-54A7C59C-1795-4122-BB79-82721C9588B6Q35747264-6AEE8EA3-7FB8-4F72-A052-C04B17BAC74AQ35834850-C9D8750D-ECBD-451E-AF8B-0F3C209BAA2FQ35899038-8A723DF7-A3B5-4586-A950-1DC9E3669E02Q35927192-06D8A32F-24C4-40F0-B14C-8A5B11C53286Q35946036-0E15C28B-1CFF-4854-B3D8-801BAE435664Q35949965-407A5F84-48A9-42DC-9450-B1E9C745D88BQ36011828-A1B09079-2942-4FCB-A767-C8CDB2F14EE9Q36145648-7991EE57-8175-42F2-8616-936DFBA9CD15Q36367336-D94129B0-A1FF-4B9B-AA46-2478D2A8A64EQ36773367-1F431D09-5571-4C97-832B-8047F916ADECQ36914988-BDCE34A4-D859-4858-AE4A-12941F2499B9Q36951647-23122CF9-DCD1-4BE1-8448-29E6C8C0B469Q37153502-CAD2812A-5BAA-4436-8A7A-89D3F584F8EEQ37756963-766606CA-C79D-4B55-8A6E-1162DF689295Q38363531-51AE54F3-D1A2-4478-A820-56A80E359C3DQ38855423-A172E98C-DCE3-4E8D-A736-1B3789FFA72FQ40038736-1E6A36C9-96F4-4A37-BE9D-0BB7173FE42FQ40239178-49F0D96D-8ED6-447F-AACE-324F49ABCF4EQ40314379-1E649075-6646-4F84-9B10-1CF7628D791CQ42176233-016572F7-4DCA-4995-9461-FA8694364524Q45800319-4BCE48EE-E40D-4F72-8525-BF666FFDB613Q46665887-902C6E18-0061-474A-8779-366AD1DB8AECQ51535624-E7F306A2-800D-447F-8BC2-685E92D49A7FQ57691255-46807D09-1EFB-487E-963D-ED832E9A15CC
P2860
Alterations in lipid kinetics in men with HIV-dyslipidemia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Alterations in lipid kinetics in men with HIV-dyslipidemia.
@en
Alterations in lipid kinetics in men with HIV-dyslipidemia.
@nl
type
label
Alterations in lipid kinetics in men with HIV-dyslipidemia.
@en
Alterations in lipid kinetics in men with HIV-dyslipidemia.
@nl
prefLabel
Alterations in lipid kinetics in men with HIV-dyslipidemia.
@en
Alterations in lipid kinetics in men with HIV-dyslipidemia.
@nl
P2093
P2860
P1476
Alterations in lipid kinetics in men with HIV-dyslipidemia
@en
P2093
B Mittendorfer
K E Yarasheski
W G Powderly
P2860
P304
P356
10.1152/AJPENDO.00118.2003
P577
2003-05-13T00:00:00Z